Reported 1 day ago
Beam Therapeutics Inc. (NASDAQ:BEAM) is gaining attention as a promising biotech stock, with H.C. Wainwright analyst Patrick Trucchio reaffirming a Buy rating and a price target of $80 due to the company's momentum in gene-editing programs. Similarly, BMO Capital’s Kostas Biliouris maintained a Buy rating with a $40 target, citing technological advancements and strong market positioning. While BEAM shows investment potential, there are suggestions that certain AI stocks might offer even greater upside.
Source: YAHOO